Securities code: 002900 securities abbreviation: Harbin Medisan Pharmaceutical Co.Ltd(002900) Announcement No.: 2022-008 Harbin Medisan Pharmaceutical Co.Ltd(002900)
Announcement on the provision for asset impairment in 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
According to the requirements of accounting standards for Business Enterprises No. 1 – inventory, accounting standards for Business Enterprises No. 8 – asset impairment and the stock listing rules of Shenzhen Stock Exchange, in order to truly, fairly and reasonably reflect the company’s financial position as of December 31, 2021, asset value and operating results in 2021, based on the principle of prudence, The company plans to withdraw 10.4307 million yuan of long-term equity investment impairment reserves from Heilongjiang weikai’er Biotechnology Co., Ltd. (hereinafter referred to as “weikai’er biotechnology”), a joint-stock company. In 2021, the company accumulated 3.0144 million yuan of inventory depreciation reserves for inventory, totaling 13.4451 million yuan of asset impairment losses. The details are as follows:
1、 Overview of provision for asset impairment
(I) provision for impairment of long-term equity investment of weikaier biological
1. Basic information
Weikai’er biology is a joint-stock company of the company. The company has invested 50 million yuan in weikai’er biology, holds 33.27% of its equity, and has a significant impact on its financial and operating policies. The company includes this investment in the “long-term equity investment” and adopts the equity method for accounting. The registered capital of weikai’er biology includes 18.83% of the preferred stock investment of other shareholders. This part of the preferred stock investment belongs to a financial liability and does not participate in the operation of the enterprise and bear the operation risk. Therefore, the proportion of voting rights (ordinary shares) actually enjoyed by the company to weikaier biology is 40.98%, and the subsequent measurement under the equity method is carried out according to this proportion.
2. Provision in previous years
Weikaier bio is mainly engaged in the R & D, production and sales of biopharmaceuticals. Its products include rapamycin, ascomycin and other immunosuppressants. Its demand side customers are mainly concentrated in India. Due to the characteristics of high investment and high risk in R & D in the pharmaceutical industry, the income of weikai’er biology in recent years can not fully make up for its costs, showing a long-term loss. The company subsequently measured the investment according to the equity method. From the investment time point to the end of 2020, the cumulative investment loss was 14.737 million yuan, and the impairment reserves of long-term equity investment were 12.4201 million yuan, 4.0233 million yuan and 3.9053 million yuan respectively at the end of 2018, 2019 and 2020 according to the evaluation results of the income method.
3. Current accrual
Due to the continuous impact of the epidemic in India, the demand for weikaier biological products fell by a cliff. The operating profit realized by weikaier biological in 2021 was far lower than the expected amount. The company continued to recognize the investment loss of 4.4836 million yuan in accordance with the equity method. In this regard, based on the principle of prudence, the company made full provision for impairment of the remaining book value of weikaier biological long-term equity investment at the end of the accounting period of 2021, with an impairment amount of 10.4307 million yuan.
(II) provision for impairment of inventories
The company made a total provision for inventory impairment of 3014400 yuan this year, mainly because the book value of some inventory commodities of the company is higher than the estimated recoverable amount. At the end of the period, according to the accounting standards for Business Enterprises No. 1 – inventory, the company remeasures the inventory value according to the lower of cost and net realizable value, in which the net realizable value of inventory is based on the estimated selling price of inventory minus the cost, estimated transportation expenses and other sales expenses to be incurred until the completion of sales and relevant taxes.
The company’s annual accumulated asset impairment loss of inventory is expected to be 3014400 yuan. See the table for details:
Project amount (RMB)
Estimated ending inventory cost: 79889836.68
Estimated recoverable amount of goods on hand at the end of the period 71833612.38
Estimated ending inventory falling price reserves 8056224.30
Less: opening inventory falling price reserves 5041843.30
It is estimated that the inventory impairment loss accrued in this fiscal year is 3014381.00
2、 Impact of the current provision for impairment on the company
The company’s provision for impairment of 13.4451 million yuan in this year is included in the company’s recurring profits and losses in 2021, reducing the company’s total profit of 13.4451 million yuan in 2021 and the owner’s equity of 13.4451 million yuan at the end of 2021. It has no impact on cash flow.
The provision for asset impairment this time is the result of the preliminary calculation of the company’s financial department, but it has been preliminarily communicated with the independent third-party evaluation organization and audit organization hired by the company. The final amount of provision for impairment will be determined after evaluation and audit by the evaluation organization and audit organization hired by the company. At that time, it will be disclosed in detail in the company’s 2021 annual report. Please pay attention to the investment risks.
3、 Explanation of the board of directors on the rationality of the provision for asset impairment loss
The board of directors of the company believes that the provision for asset impairment is made based on the principle of prudence, in line with the accounting standards for business enterprises, the stock listing rules of Shenzhen Stock Exchange and the relevant accounting policies of the company. The basis for the provision for asset impairment is sufficient and fairly reflects the asset status, asset value and operating results of the company, Make the company’s accounting information about asset value more authentic, reliable and reasonable.
It is hereby announced.
Harbin Medisan Pharmaceutical Co.Ltd(002900) board of directors January 28, 2022
